Johnson & Johnson’s Phase 3 MajesTEC-3 study shows that the combination of teclistamab and subcutaneous daratumumab (tec+dara) significantly improves outcomes for relapsed or refractory multiple myeloma...
EFPIA’s new report urges clearer, lifecycle-wide governance for AI in pharmaceuticals. Drawing on cross-sector insights, it calls for clarifying AI exemptions, strengthening regulator–industry dialogue, harmonizing expectations,...
Spain’s funding of new cancer drugs hinges mainly on substantial clinical benefit and quality-of-life data, while efficiency and innovation have little influence. Evidence quality speeds decisions,...
The EIB and Angelini Ventures will jointly invest €150 million over six years to support 7–10 high-potential European biotech, medtech, and digital health startups nearing commercial...
NurExone Biologic Inc.’s nomination for the 2025 Prix Galien Bridges Award places it alongside Roche and Novo Nordisk, highlighting its rising global visibility. Its exosome-based regenerative...
Farmaindustria’s Farma-Biotech program links researchers and start-ups with pharmaceutical companies to advance innovative medicines. At its 26th cooperation meeting, seven Spanish projects in oncology, obesity, nephrology,...
A VHIR–VHIO study developed ImmunoPET, a PET-based “virtual biopsy” using a radiolabeled antibody to detect LIF in glioblastoma. It noninvasively maps tumor heterogeneity, identifies patients suited...
The Biotech Act enters a decisive phase as Parliament prepares to vote on an alternative compromise on December 2, replacing the rapporteur’s blocked report. Simultaneously, the...
Endeavor Chile’s Biotech Route reveals that Chilean biotech scaleups see internationalization as essential, but face major barriers: scarce international financing, complex foreign regulations, and limited commercial...
The EMA recommended EU approval of Waskyra, a single-dose gene therapy for patients 6 months and older with Wiskott-Aldrich syndrome who lack a suitable HSCT donor....